Insiders Make Bold Move as Key Players Double Down on Aktis Oncology
TipRanks (Wed, 14-Jan 9:02 PM ET)
Globe Newswire (Tue, 13-Jan 6:30 AM ET)
Major Insider Moves Signal Growing Confidence in Aktis Oncology
TipRanks (Mon, 12-Jan 9:01 PM ET)
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Business Wire (Fri, 9-Jan 12:58 PM ET)
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Aktis Oncology trades on the NASDAQ stock market under the symbol AKTS.
As of January 15, 2026, AKTS stock price declined to $20.43 with 89,313 million shares trading.
AKTS has a market cap of $1.07 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that AKTS belongs to (by Net Assets): BMED.
AKTS support price is $18.95 and resistance is $22.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTS shares will trade within this expected range on the day.
